Recent blog posts
Lupin Announces the Successful Completion of Phase 3 Trials for Lucentis® Biosimilar
Latest Hotspot
3 min read
Lupin Announces the Successful Completion of Phase 3 Trials for Lucentis® Biosimilar
8 August 2024
Global Pharma major Lupin Limited revealed the completion of an international Phase 3 clinical trial for its biosimilar LUBT010.
Read →
Successful Phase II Trial of Levicept's Novel Osteoarthritis Treatment LEVI-04
Latest Hotspot
3 min read
Successful Phase II Trial of Levicept's Novel Osteoarthritis Treatment LEVI-04
8 August 2024
Levicept Reveals Successful Phase II Trial Results for LEVI-04, a Novel Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis.
Read →
US Phase 2 Trial of Akeso’s Ligufalimab-Azacitidine Combo for Myelodysplastic Syndrome Begins
Latest Hotspot
3 min read
US Phase 2 Trial of Akeso’s Ligufalimab-Azacitidine Combo for Myelodysplastic Syndrome Begins
8 August 2024
First Patient Enrolled in US Phase 2 Trial of Akeso’s Ligufalimab and Azacitidine Combo for Myelodysplastic Syndrome.
Read →
Genmab Assumes Complete Responsibility for Acasunlimab Development Initiative
Latest Hotspot
3 min read
Genmab Assumes Complete Responsibility for Acasunlimab Development Initiative
8 August 2024
Genmab A/S revealed that it will take over full responsibilities for both the ongoing development and possible commercialization of acasunlimab.
Read →
FDA Approves Rezolute's Phase 3 Study of RZ358 for Tumor-Induced Hypoglycemia
Latest Hotspot
3 min read
FDA Approves Rezolute's Phase 3 Study of RZ358 for Tumor-Induced Hypoglycemia
8 August 2024
Rezolute Receives FDA Approval for Phase 3 IND Study of RZ358 for Hypoglycemia Caused by Tumor-Induced Hyperinsulinism.
Read →
Imbrium Therapeutics Files Application to Study Sunobinop for Alcohol Use Disorder Treatment
Latest Hotspot
3 min read
Imbrium Therapeutics Files Application to Study Sunobinop for Alcohol Use Disorder Treatment
8 August 2024
Imbrium Therapeutics L.P., has filed an Investigational New Drug Application with the U.S. Food and Drug Administration to assess the use of sunobinop for potentially treating moderate to severe alcohol use disorder.
Read →
Bayer's FINEARTS-HF Phase III Study on KERENDIA® Shows Positive Results in Heart Failure Patients
Latest Hotspot
3 min read
Bayer's FINEARTS-HF Phase III Study on KERENDIA® Shows Positive Results in Heart Failure Patients
7 August 2024
Bayer Reveals Phase III Study Results: FINEARTS-HF Achieves Key Goal for KERENDIA® (finerenone) in Heart Failure Patients with Mildly Reduced or Normal Ejection Fraction.
Read →
Innovent and SanegeneBio Begin Early-Stage Trial for IBI3016 (AGT siRNA)
Latest Hotspot
3 min read
Innovent and SanegeneBio Begin Early-Stage Trial for IBI3016 (AGT siRNA)
7 August 2024
Innovent and SanegeneBio Announce Initial Dosing of Participant in Early-Stage Trial of IBI3016 (AGT siRNA).
Read →
FDA Approves Jemperli for All Advanced Endometrial Cancer Patients, Marking First Immunotherapy with Proven Survival Benefits
Latest Hotspot
3 min read
FDA Approves Jemperli for All Advanced Endometrial Cancer Patients, Marking First Immunotherapy with Proven Survival Benefits
7 August 2024
The US FDA extends approval for Jemperli (dostarlimab-gxly) combined with chemotherapy to all adults with advanced or recurrent endometrial cancer. It is the first immunotherapy showing overall survival benefits.
Read →
FDA Accelerated Approval for Adaptimmune's TECELRA®, U.S's First Engineered Cell Therapy for Solid Tumors
Latest Hotspot
3 min read
FDA Accelerated Approval for Adaptimmune's TECELRA®, U.S's First Engineered Cell Therapy for Solid Tumors
7 August 2024
Adaptimmune Gains FDA Accelerated Approval for TECELRA® (afamitresgene autoleucel), the First Engineered Cell Therapy for Solid Tumors in the U.S.
Read →
Evorpacept Enhances Tumor Response in HER2+ Gastric Cancer: ALX Oncology's ASPEN-06 Trial
Latest Hotspot
3 min read
Evorpacept Enhances Tumor Response in HER2+ Gastric Cancer: ALX Oncology's ASPEN-06 Trial
7 August 2024
ALX Oncology's Phase 2 ASPEN-06 Trial Shows Evorpacept Enhances Tumor Response in HER2-Positive Gastric Cancer Patients.
Read →
Instil Bio and ImmuneOnco Partner for IMM2510 and IMM27M Development
Latest Hotspot
3 min read
Instil Bio and ImmuneOnco Partner for IMM2510 and IMM27M Development
7 August 2024
Instil Bio and ImmuneOnco reveal partnership for IMM2510, a leading PD-L1xVEGF bispecific antibody, and IMM27M, an advanced anti-CTLA-4 antibody.
Read →